Survey of triamcinolone acetonide for ocular diseases in Japan

Taiji Sakamoto, Tetsuo Hida, Yasuo Tano, Akira Negi, Shinobu Takeuchi, Tatsuro Ishibashi, Yoshitsugu Inoue, Nobuyuki Ohguro, Annabelle Ayame Okada

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE: To survey the use of triamcinolone acetonide (TA) for ocular disease in Japan. SUBJECTS AND METHODS: A questionnaire was sent to 1,236 teaching hospitals approved by the Japanese Ophthalmological Society requesting information regarding indications, methods, efficacy and complications of TA administered from January through December 2005. The survey specifically covered the use of TA in intravitreal injections, sub-Tenon's injections and intraoperatively during vitrectomy procedures. RESULTS: Four-hundred and fifty-nine hospitals responded to the survey (response rate 36.9%) involving TA use in 44,827 eyes. Intravitreal injections of TA were administered to 5,665 eyes in 159 hospitals. The average dose was 6.53 mg for a single injection and was reported to have highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Complications included cataract formation in 116 eyes (2.04%), glaucoma requiring filtration surgery in 32 eyes (0.56%), endophthalmitis in 7 eyes (0.12%), and blepharoptosis in 8 eyes (0.14%). Sub-Tenon's injections of TA were administered to 12,343 eyes in 308 hospitals. The average dose was 19.87 mg for a single injection and had the highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Sub-Tenon's administration of TA was also frequently used for uveitis. Complications reported were cataract formation in 191 eyes (1.55%), glaucoma requiring filtration surgery in 33 eyes (0.26%), endophthalmitis in 1 eye (0.008%), periocular infection in 5 eyes (0.04%) and blepharoptosis in 43 eyes (0.35%). TA was used as an adjunct to vitrectomy in 26,819 eyes in 270 hospitals and was judged to be most useful in the separation of posterior hyaloid from the retina. Complications included cataract formation in 49 eyes (0.18%), glaucoma requiring filtration surgery in 32 eyes (0.56%), and endophthalmitis in 7 eyes (0.026%). CONCLUSIONS: TA is being widely administered for ocular diseases in Japan, and appears to have good efficacy in a variety of indications. Several complications related to TA use were reported, however the rates of complications were low.

Original languageEnglish
Pages (from-to)936-945
Number of pages10
JournalNippon Ganka Gakkai zasshi
Volume111
Issue number12
Publication statusPublished - Dec 2007

Fingerprint

Triamcinolone Acetonide
Eye Diseases
Japan
Filtering Surgery
Endophthalmitis
Glaucoma
Cataract
Blepharoptosis
Surveys and Questionnaires
Retinal Vein Occlusion
Intravitreal Injections
Injections
Macular Edema
Vitrectomy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Sakamoto, T., Hida, T., Tano, Y., Negi, A., Takeuchi, S., Ishibashi, T., ... Okada, A. A. (2007). Survey of triamcinolone acetonide for ocular diseases in Japan. Nippon Ganka Gakkai zasshi, 111(12), 936-945.

Survey of triamcinolone acetonide for ocular diseases in Japan. / Sakamoto, Taiji; Hida, Tetsuo; Tano, Yasuo; Negi, Akira; Takeuchi, Shinobu; Ishibashi, Tatsuro; Inoue, Yoshitsugu; Ohguro, Nobuyuki; Okada, Annabelle Ayame.

In: Nippon Ganka Gakkai zasshi, Vol. 111, No. 12, 12.2007, p. 936-945.

Research output: Contribution to journalArticle

Sakamoto, T, Hida, T, Tano, Y, Negi, A, Takeuchi, S, Ishibashi, T, Inoue, Y, Ohguro, N & Okada, AA 2007, 'Survey of triamcinolone acetonide for ocular diseases in Japan', Nippon Ganka Gakkai zasshi, vol. 111, no. 12, pp. 936-945.
Sakamoto T, Hida T, Tano Y, Negi A, Takeuchi S, Ishibashi T et al. Survey of triamcinolone acetonide for ocular diseases in Japan. Nippon Ganka Gakkai zasshi. 2007 Dec;111(12):936-945.
Sakamoto, Taiji ; Hida, Tetsuo ; Tano, Yasuo ; Negi, Akira ; Takeuchi, Shinobu ; Ishibashi, Tatsuro ; Inoue, Yoshitsugu ; Ohguro, Nobuyuki ; Okada, Annabelle Ayame. / Survey of triamcinolone acetonide for ocular diseases in Japan. In: Nippon Ganka Gakkai zasshi. 2007 ; Vol. 111, No. 12. pp. 936-945.
@article{77cc34543806419d978aecf30f1e7233,
title = "Survey of triamcinolone acetonide for ocular diseases in Japan",
abstract = "PURPOSE: To survey the use of triamcinolone acetonide (TA) for ocular disease in Japan. SUBJECTS AND METHODS: A questionnaire was sent to 1,236 teaching hospitals approved by the Japanese Ophthalmological Society requesting information regarding indications, methods, efficacy and complications of TA administered from January through December 2005. The survey specifically covered the use of TA in intravitreal injections, sub-Tenon's injections and intraoperatively during vitrectomy procedures. RESULTS: Four-hundred and fifty-nine hospitals responded to the survey (response rate 36.9{\%}) involving TA use in 44,827 eyes. Intravitreal injections of TA were administered to 5,665 eyes in 159 hospitals. The average dose was 6.53 mg for a single injection and was reported to have highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Complications included cataract formation in 116 eyes (2.04{\%}), glaucoma requiring filtration surgery in 32 eyes (0.56{\%}), endophthalmitis in 7 eyes (0.12{\%}), and blepharoptosis in 8 eyes (0.14{\%}). Sub-Tenon's injections of TA were administered to 12,343 eyes in 308 hospitals. The average dose was 19.87 mg for a single injection and had the highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Sub-Tenon's administration of TA was also frequently used for uveitis. Complications reported were cataract formation in 191 eyes (1.55{\%}), glaucoma requiring filtration surgery in 33 eyes (0.26{\%}), endophthalmitis in 1 eye (0.008{\%}), periocular infection in 5 eyes (0.04{\%}) and blepharoptosis in 43 eyes (0.35{\%}). TA was used as an adjunct to vitrectomy in 26,819 eyes in 270 hospitals and was judged to be most useful in the separation of posterior hyaloid from the retina. Complications included cataract formation in 49 eyes (0.18{\%}), glaucoma requiring filtration surgery in 32 eyes (0.56{\%}), and endophthalmitis in 7 eyes (0.026{\%}). CONCLUSIONS: TA is being widely administered for ocular diseases in Japan, and appears to have good efficacy in a variety of indications. Several complications related to TA use were reported, however the rates of complications were low.",
author = "Taiji Sakamoto and Tetsuo Hida and Yasuo Tano and Akira Negi and Shinobu Takeuchi and Tatsuro Ishibashi and Yoshitsugu Inoue and Nobuyuki Ohguro and Okada, {Annabelle Ayame}",
year = "2007",
month = "12",
language = "English",
volume = "111",
pages = "936--945",
journal = "Journal of Japanese Ophthalmological Society",
issn = "0029-0203",
publisher = "Nippon Ganka Gakkai",
number = "12",

}

TY - JOUR

T1 - Survey of triamcinolone acetonide for ocular diseases in Japan

AU - Sakamoto, Taiji

AU - Hida, Tetsuo

AU - Tano, Yasuo

AU - Negi, Akira

AU - Takeuchi, Shinobu

AU - Ishibashi, Tatsuro

AU - Inoue, Yoshitsugu

AU - Ohguro, Nobuyuki

AU - Okada, Annabelle Ayame

PY - 2007/12

Y1 - 2007/12

N2 - PURPOSE: To survey the use of triamcinolone acetonide (TA) for ocular disease in Japan. SUBJECTS AND METHODS: A questionnaire was sent to 1,236 teaching hospitals approved by the Japanese Ophthalmological Society requesting information regarding indications, methods, efficacy and complications of TA administered from January through December 2005. The survey specifically covered the use of TA in intravitreal injections, sub-Tenon's injections and intraoperatively during vitrectomy procedures. RESULTS: Four-hundred and fifty-nine hospitals responded to the survey (response rate 36.9%) involving TA use in 44,827 eyes. Intravitreal injections of TA were administered to 5,665 eyes in 159 hospitals. The average dose was 6.53 mg for a single injection and was reported to have highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Complications included cataract formation in 116 eyes (2.04%), glaucoma requiring filtration surgery in 32 eyes (0.56%), endophthalmitis in 7 eyes (0.12%), and blepharoptosis in 8 eyes (0.14%). Sub-Tenon's injections of TA were administered to 12,343 eyes in 308 hospitals. The average dose was 19.87 mg for a single injection and had the highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Sub-Tenon's administration of TA was also frequently used for uveitis. Complications reported were cataract formation in 191 eyes (1.55%), glaucoma requiring filtration surgery in 33 eyes (0.26%), endophthalmitis in 1 eye (0.008%), periocular infection in 5 eyes (0.04%) and blepharoptosis in 43 eyes (0.35%). TA was used as an adjunct to vitrectomy in 26,819 eyes in 270 hospitals and was judged to be most useful in the separation of posterior hyaloid from the retina. Complications included cataract formation in 49 eyes (0.18%), glaucoma requiring filtration surgery in 32 eyes (0.56%), and endophthalmitis in 7 eyes (0.026%). CONCLUSIONS: TA is being widely administered for ocular diseases in Japan, and appears to have good efficacy in a variety of indications. Several complications related to TA use were reported, however the rates of complications were low.

AB - PURPOSE: To survey the use of triamcinolone acetonide (TA) for ocular disease in Japan. SUBJECTS AND METHODS: A questionnaire was sent to 1,236 teaching hospitals approved by the Japanese Ophthalmological Society requesting information regarding indications, methods, efficacy and complications of TA administered from January through December 2005. The survey specifically covered the use of TA in intravitreal injections, sub-Tenon's injections and intraoperatively during vitrectomy procedures. RESULTS: Four-hundred and fifty-nine hospitals responded to the survey (response rate 36.9%) involving TA use in 44,827 eyes. Intravitreal injections of TA were administered to 5,665 eyes in 159 hospitals. The average dose was 6.53 mg for a single injection and was reported to have highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Complications included cataract formation in 116 eyes (2.04%), glaucoma requiring filtration surgery in 32 eyes (0.56%), endophthalmitis in 7 eyes (0.12%), and blepharoptosis in 8 eyes (0.14%). Sub-Tenon's injections of TA were administered to 12,343 eyes in 308 hospitals. The average dose was 19.87 mg for a single injection and had the highest efficacy in eyes with diabetic macular edema, followed by retinal vein occlusion. Sub-Tenon's administration of TA was also frequently used for uveitis. Complications reported were cataract formation in 191 eyes (1.55%), glaucoma requiring filtration surgery in 33 eyes (0.26%), endophthalmitis in 1 eye (0.008%), periocular infection in 5 eyes (0.04%) and blepharoptosis in 43 eyes (0.35%). TA was used as an adjunct to vitrectomy in 26,819 eyes in 270 hospitals and was judged to be most useful in the separation of posterior hyaloid from the retina. Complications included cataract formation in 49 eyes (0.18%), glaucoma requiring filtration surgery in 32 eyes (0.56%), and endophthalmitis in 7 eyes (0.026%). CONCLUSIONS: TA is being widely administered for ocular diseases in Japan, and appears to have good efficacy in a variety of indications. Several complications related to TA use were reported, however the rates of complications were low.

UR - http://www.scopus.com/inward/record.url?scp=40349089154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349089154&partnerID=8YFLogxK

M3 - Article

C2 - 18186215

AN - SCOPUS:40349089154

VL - 111

SP - 936

EP - 945

JO - Journal of Japanese Ophthalmological Society

JF - Journal of Japanese Ophthalmological Society

SN - 0029-0203

IS - 12

ER -